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Simple Summary: Reversible epithelial to mesenchymal transition (EMT) plays a key role in estab-
lishing a malignant phenotype by assuring cancer cell plasticity critical for cancer progression by
allowing a small fraction of cancer cells to detach from primary lesions and outgrow at metastatic
sites. Cancer cell plasticity is associated with cancer stem cell properties contributing to chemoresis-
tance, metastasis, and poor clinical outcomes. Dysregulated RNA-binding proteins are key players in
controlling the RNA metabolism, including mRNA processing, export, and translation, and have
been implicated in cancer cell plasticity. In this study, we demonstrated that aberrantly expressed
RNA-binding protein La is critical for transforming growth factor β-induced EMT and for gaining
cancer stem cell properties. Understanding the function of aberrant RNA-binding protein expression
in cancer cell plasticity reveals prospects for identifying novel therapeutic targets.
Abstract: Background: the aberrant overexpression of predominantly nuclear localizing RNA-
binding protein (RBP) La contributes to proliferation, mobility, and chemoresistance of cancer
cells and tumor growth in mice. Methods: studies included cancer tissue microarrays (TMAs)
analyses, cancer tissue data mining, transforming growth factor β (TGFβ)-induced cancer cell
plasticity studies, three dimensional sphere growth, epithelial to mesenchymal transition (EMT)
assays, analysis of cancer stem cell (CSC) marker expression, and post-translational modification
of cancer-associated La protein. Results: we demonstrated that significant overexpression of RBP
La in lung and head and neck cancer tissue correlates with poor overall survival. Furthermore,
small interfering RNA-mediated depletion of La reduced proliferation and migration of cancer
cells, blocked TGFβ-induced EMT, and diminished both EMT and CSC marker expression. Rescue
experiments with La wildtype but not RNA chaperone domain activity-defective La mutant increased
the expression of those cancer progression markers, suggesting a critical role of La’s RNA chaperone
activity in this process. La depletion in cancer cells also significantly decreased sphere growth in the
presence of TGFβ. Interestingly, TGFβ treatment induced phosphorylation of La at threonine 389
(pLaT389) only in adherents but not in 3D growing cultures. Conclusion: our study suggests that the
TGFβ/AKT/pLaT389 signaling pathway regulates cancer cell plasticity.
Keywords: La protein; La/SSB; LaRP3; RNA-binding protein; RBP; plasticity; TGFβ; EMT; cancer
stem cells; CSC; AKT; phosphorylation
1. Introduction
Ribonucleic acid (RNA)-binding proteins (RBP) are critical players of the RNA metabolism
and regulate transcription, processing, editing, localization, stability, and translation of
RNAs. To fulfill their manifold functions RBPs localize to the nucleus, the cytoplasm, or
shuttle between both compartments and often accumulate in nuclear structures such as the
nucleolus or splicing speckles. Dysregulation of RBPs is frequently associated with cancer
progression. The function of RBPs is widely regulated by post-translational modifications
(PTMs), including phosphorylation, acetylation, methylation, ubiquitinylation, and sumoy-
lation, and are often allow a fast response to cellular signaling events [1,2]. By binding
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target RNAs, the RBPs form complexes, called ribonucleoproteins (RNPs). In cancer cells,
aberrant expression and dysregulated PTMs of RBPs can change the binding activity and
processing of target RNAs supporting a malignant phenotype [3].
The RBP La (La-related protein 3 (LARP3), Sjogren syndrome antigen B (SSB)) be-
longs to the La-related protein (LARP) family, characterized by an RNA-binding domain
called La motif [4,5]. Potential functions of the different LARP family members in cancer
pathobiology have been recently reviewed [6]. The La protein predominantly localizes to
the nucleoplasm, but also shuttles between the nucleus and cytoplasm [7]. The RBP La is
overexpressed in various cancer entities including chronic myeloid leukemia, head and
neck, and cervical cancer [2]. Aberrant La protein expression contributes to increased prolif-
eration, migration, invasion, and chemoresistance of cancer cells [8,9] and supports tumor
growth in mice [10]. Investigating the cellular functions revealed that La assists processing
of noncoding RNA precursors (pre-transfer (pre-t)RNA, pre-micro (pre-mi)RNA) [11],
but also stimulates translation of target messenger RNAs (mRNAs) encoding oncogenic
factors (reviewed in: [2]). In cancer cells, La-dependent translation of target mRNAs causes
increased expression of cell cycle regulator cyclin D1 [9], p53-negative regulator mouse dou-
ble minute 2 (Mdm2) [12], extracellular matrix protein laminin B1 [13], and antiapoptotic
factors B-cell lymphoma 2 (Bcl2) and X-linked inhibitor of apoptosis protein (XIAP) [14,15].
All of those target mRNAs encode oncogenic factors known to contribute to cancer pro-
gression and—when aberrantly expressed—often correlate with poor clinical outcomes.
Recently, we identified an RNA chaperone domain (RCD) in the carboxyterminal part of
RBP La that is able to unwind RNA stem-loop structures located within the 5′-untranslated
region (5′UTR) of cyclin D1 and Bcl2 mRNA, hindering efficient translation in vitro and
in cell-based assays [14,16], supporting a model that suggests that the RNA chaperone
activity of La contributes to overexpression of oncogenic factors in cancer cells.
Cancer cell plasticity is the capability of cancer cells to reversibly switch between
epithelial and mesenchymal states in response to extracellular signals. Epithelial to mes-
enchymal transition (EMT) plays a key role during establishing a malignant cancer pheno-
type [17]. EMT is associated with higher cell motility, increased resistance to apoptosis, and
cancer stem cell (CSC) properties, resulting in chemoresistance, metastasis, and poor clini-
cal outcomes. CSCs have been identified in various cancer entities, including lung and head
and neck cancer, and represent a small cell population with the ability of self-renewal, a vast
differentiation potential, and high chemoresistance driving tumor recurrence and metasta-
sis [18]. When growing in nonadherent serum-free conditions, CSCs form multicellular
three-dimensional (3D) spheres [19]. Transforming growth factor β (TGFβ) is a well-known
extracellular signal-inducing EMT via the activation of the canonical SMAD pathway
and the noncanonical pathways, including protein kinase B (PKB)/AKT, extracellular
signal-regulated kinase (ERK), and mitogen-activated protein kinase (MAPK) [20]. A dis-
tinguished intracellular master regulator of EMT is zinc finger E-box binding homeobox 1
(ZEB1), a transcription factor establishing a pro-metastatic state in cancer cells [21,22].
Herein, we show that the cancer-associated RNA chaperone La is required for TGFβ-
induced EMT, elevated expression of transcriptional EMT master regulator ZEB1, and
supports cancer stem cell properties as indicated by higher CSC marker expression and
increased sphere formation and growth. Interestingly, during EMT, TGFβ stimulates—in
an AKT-dependent manner—phosphorylation of La at threonine 389 under adherent but
not sphere growth conditions. Overall, this study presents the first data highlighting an
important role of RBP La in cancer cell plasticity.
2. Results
2.1. Overexpression of RNA-Binding Protein La Correlates with Reduced Overall Survival in
Patients and Contributes to Increased Proliferation and Migration of Cancer Cells
For lung cancer, the analysis of microarray-based datasets available through the data-
mining platform ONCOMINE revealed a twofold increase of La mRNA level in lung
cancer tissue, which correlated with poor prognosis in non-small-cell carcinoma (NSCLC)
patients [23]. To establish a more comprehensive picture of aberrant La protein expression
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in lung cancer, we analyzed by immunohistochemistry the La protein expression in two
lung cancer tissue microarrays consisting of (A) 51 squamous cell carcinoma (SCC) along
with 50 normal cancer adjacent tissues samples (TMA: BC04118) and (B) 49 adenocarci-
noma along with 48 normal cancer adjacent tissues (TMA: LC1002). Our data underline a
significant overexpression of the RNA-binding protein La in both SCC and adenocarcinoma
lung tissues when compared to normal adjacent lung tissues (Figure 1A,B). Analyzing RBP
La expression in regard to different cancer stages revealed a consistently high expression
in SCC (Figure S1A) and decreased expression in higher compared to lower cancer stages
in adenocarcinoma (Figure S1B). In regard to sex differences, neither in SCC nor in adeno-
carcinoma was a significant change of La expression observed (Figure S2A,C (male) and
Figure S2B,D (female)).
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noma (normal: n = 48/SCC: n = 49; TMA LC1002). Representative images of adjacent normal tissue 
and cancer tissue are presented, scale 100-fold magnification. The predominantly nuclear staining 
of the RBP La is depicted as percentages based on the largest population of benign cells present in 
normal tissue, respectively, tumor cells present in cancer tissue (p value: < 0.001 (three asterisks)). 
Significant overexpression of the La protein in head and neck SCC has been pub-
lished earlier [8]. To test whether an elevated La mRNA level correlates with the poor 
survival of patients, we mined the publicly available datasets R2: Genomics Analysis and 
Visualization Platform (http://r2.amc.nl). For head and neck SCC the Kaplan–Meier over-
all survival curve revealed a significant 32-month reduction in the 0.5 overall survival 
probabilities of patients with high La mRNA expression, when compared to patients with 
low La mRNA expression (Figure 2A). Similarly, lung adenocarcinoma data showed a 
significant 8-month reduction in the 0.5 overall survival probabilities of patients with high 
La mRNA expression, when compared to patients with low La mRNA expression (Figure 
2B).  
Figure 1. The ribonucleic acid (RNA)-binding proteins (RBP) La is overexpressed in lung cancer
tissue. Immunohistochemistry of two distinct tissue microarrays (TMAs) demonstrating significant
overexpression of the La protein in lung cancer tissue compared to normal cancer adjacent tissue.
(A) Squamous cell carcinoma (nor l: n = 50/SCC: n = 51; TMA BC04118), (B) adenoc rci ma
(normal: n = 48/SCC: n = 49; TMA LC1002). Representativ images of djacent normal tissue and
cancer tissue are pres nted, scale 100-fold magnification. The predominantly nuclear staining of the
RBP La is depicte as percentages based on the largest population f benign cells present in no mal
tissue, respectively, tumor cells present in cancer tissue (p value: < 0.001 (three asterisks)).
Significant overexpression of the La protein in head and neck SCC has been published
earlier [8]. To test whether an elevated La mRNA level correlates with the poor survival of
patients, we mined the publicly available datasets R2: Genomics Analysis and Visualization
Platform (http://r2.amc.nl). For head and neck SCC the Kaplan–Meier overall survival
curve revealed a significant 32-month reduction in the 0.5 overall survival probabilities
of patients with high La mRNA expression, when compared to patients with low La
mRNA expression (Figure 2A). Similarly, lung adenocarcinoma data showed a significant
8-month reduction in the 0.5 overall survival probabilities of patients with high La mRNA
expression, when compared to patients with low La mRNA expression (Figure 2B).
Taken together, both the La protein and its mRNA expression are elevated in cancer
tissue. The overall survival curves showed that in both cancer entities the patients’ survival
probability was significantly reduced when La mRNA levels were elevated. These data
further accentuate the necessity to understand the functional role of elevated La expression
in cancer pathobiology.




Figure 2. High La expression is associated with poor overall survival. (A) The analysis revealed that at an overall survival 
probability of 0.5, head and neck squamous cell carcinoma (SCC) patient survival was reduced by 32 months when La 
expression was high. Head and neck SCC gene expression dataset TCGA-520 was analyzed for the single La gene. A gene 
expression cut off of 1713 was applied; the Chi-square test (Chi = 12.02) and p value (p = 5.3 × 10−4) was calculated. (B) The 
analysis revealed that at an overall survival probability of 0.5, lung adenocarcinoma patient survival was reduced by 8 
months when La expression was high. Lung adenocarcinoma gene expression dataset TCGA-515 was analyzed for the 
single La gene. A gene expression cut off of 1791 was applied; the Chi-square test (Chi = 8.63) and p value (p = 3.3 × 10−3) 
was calculated. 
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As shown previously, depletion of the La protein reduces unrestricted cancer cell 
proliferation of cancer cell lines originating from different cancer entities, including cervi-
cal, prostate, and head and neck cancer [8,9]. Concordantly, shRNA-mediated La deple-
tion significantly diminished proliferation of lung cancer cells (Figure 3A). Furthermore, 
our wound healing assays demonstrated that migration was reduced in La-depleted lung 
cancer cells (Figure 3B,C), which confirms data obtained in head and neck cancer cells 
studies completed earlier [8]. Taken together, consistently with findings in head and neck 
cancer, the La protein is overexpressed in lung cancer tissue, elevated La mRNA expres-
sion correlates with poor overall survival of lung cancer patients, and cancer-associated 
La protein is required for proliferation and migration of lung cancer cells. 
Figure 2. High La expression is associated with poor overall survival. (A) The analysis revealed that at an overall survival
probability of 0.5, head and neck squamous cell carcinoma (SCC) patient survival was reduced by 32 months when La
expression was high. Head and neck SCC gene expression dataset TCGA-520 was analyzed for the single La gene. A
gene expression cut off of 1713 was applied; the Chi-square test (Chi = 12.02) and p value (p = 5.3 × 10−4) was calculated.
(B) The analysis revealed that at an overall survival probability of 0.5, lung adenocarcinoma patient survival was reduced
by 8 months when La expression was igh. Lung adenocarcinoma gene expr i ataset TCGA-515 was an lyzed for the
single La gene. A gene expr ff of 1791 was ap lied; the Chi-square test (Chi = 8.63) and p value (p = 3.3 × 10−3)
was calculated.
As shown previously, depletion of the La protein reduces unrestricted cancer cell
proliferation of cancer cell lines originating from different cancer entities, including cervical,
prostate, and head and neck cancer [8,9]. Concordantly, shRNA-mediated La depletion
significantly diminished proliferation of lung cancer cells (Figure 3A). Furthermore, our
wound healing assays demonstrated that migration was reduced in La-depleted lung
cancer cells (Figure 3B,C), which confirms data obtained in head and neck cancer cells
studies completed earlier [8]. Taken together, consistently with findings in head and neck
cancer, the La protein is overexpressed in lung cancer tissue, elevated La mRNA expression
correlates with poor overall survival of lung cancer patients, and cancer-associated La
protein is required for proliferation and migration of lung cancer cells.
2.2. TGFβ-Induced Epithelial to Mesenchymal Transition Is Dependent on the La Protein
To investigate whether the RBP La plays a role in cancer cell plasticity, we studied
TGFβ-induced epithelial to mesenchymal tra sition (EMT) in control and La-depleted
cancer cells. Treatment with TGFβ [5 ng/mL] for 72 h induced transition of a cobblestone-
like, epithelial to a fibroblastic or mesenchy al phenotype in control-treated but not in
La-depleted cancer cells, as shown for A549 lung cancer cells (Figure 4A and Figure S3)
and SCC22A head and neck cancer cells (Figure 4B). Immunoblot analyses confirmed
that the TGFβ-induced transition from the epithelial to mesenchymal phenotype was
paralleled by increased expression of EMT marker N-cadherin in control-treated but not
La-depleted A549 cells (Figure 4C) and SCC22A cells (Figure 4D). Due to the pronounced
EMT phenotype in SCC22A cells, we decided to focus on SCC22A cells for further studies,
aiming to test our hypothesis that the La protein contributes to cancer cell plasticity. A
more in-depth analysis of TGFβ-treated SCC22A cells revealed—as expected for cancer
cells undergoing EMT—reduced expression of epithelial marker zonula occludens-1 (ZO-1)
paralleled by augmented protein expression of mesenchymal marker N-cadherin, EMT
marker vimentin, and transcriptional EMT master regulator ZEB1 in control-treated but
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not La-depleted cancer cells upon TGFβ treatment (Figure 5 and Figure S3). These data
clearly demonstrate that the La protein mediates TGFβ-induced EMT.
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La depletion was performed by expression of two independent shRNAs (shLa_1, shLa_2) com-
pared to control shRNA (shCon). (A) Proliferation and (B) wound healing assays, AU = arbitrary 
units. (C) Representative images of control- and La-depleted lung adenocarcinoma A549 cells 24 h 
after wound scratching. Scale bar 200 µm. (p value: < 0.05 (one asterisk), < 0.005 (two asterisks), < 
0.001 (three asterisks), n = 3). 
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Figure 5. Reduced expression of cellular markers defining EMT and cancer cell stemness in TGFβ-
treated and La-depleted cells. Depletion of La reduces the expression of EMT marker ZO-1, N-
cadherin, Vimentin, and ZEB1. In addition, the cancer cell stemness marker CD44 and Bmi1 are 
diminished in TGFβ-treated and La-depleted SCC22A cells. IB: immunoblot. TGFβ (plus) [5 
Figure 4. Depletion of La reduces transforming growth factor β (TGFβ)-induced EMT in lung and
and neck cancer cells. La depletion blocks the TGFβ-induced transit on from epithelial to
esenchymal phenotype in (A) lung adenocarcinoma A549 and (B) head and neck squamous cell
carcinoma SCC22A cells (representative images of at least three independent experiments (n = 3),
scale 200-fold magnification). Reduced expression of EMT marker N-cadherin in TGFβ-treated and
La-depleted (C) A549 and (D) SC 22A cells. IB: i munoblot. TGFβ (plus) [5 ng/mL] or vehicle
(minus) [1 mg/mL BSA in 4 mM Cl] treatment. Numbers below the bands represent the protein
expression normalized to GAPDH.
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Figure 5. Reduced expression of cellular markers defining EMT and cancer cell stemness in TGFβ-
treated and La-depleted cells. Depletion of La reduces the expression of EMT marker ZO-1, N-
cadherin, Vimentin, and ZEB1. In addition, the cancer cell stemness marker CD44 and Bmi1 are
diminished in TGFβ-treated and La-depleted SCC22A cells. IB: immunoblot. TGFβ (plus) [5 ng/mL]
or vehicle (minus) [1 mg/mL BSA i 4 mM HCl] treatment. Numbers below the bands represent the
protein expression normalized to GAPDH.
2.3. The La Protein Supports a Cancer Stem Cell-Like Phenotype
During EMT, cancer cells often gain cancer stem cell (CSC) properties, which are char-
acterized by an increased expression of CSC markers and the ability to grow under serum-
free conditions in ultra-low attachment plates as three-dimensional (3D) spheres. First, we
tested whether the expression of two CSC markers, namely cluster of differentiation 44
(CD44) and B lymphoma Mo-MLV insertion region 1 homolog (Bmi1) [24], are changed in
TGFβ- and control-treated cells. Immunoblot analysis showed that the expression of CD44
and Bmi1 was significantly increased in TGFβ-treated compared to control-treated cells
(Figure 5 and Figure S5). In contrast, in TGFβ-treated and La-depleted cells the expression
of both CSC markers was distinctly reduced, suggesting that the expression of RBP La
supports CSC properties in cancer cells that had undergone TGFβ-induced EMT.
Recently, we identified a novel RNA chaperone domain (RCD) in the carboxyterminal
part of the La protein (Figure 6A and Figure S4) and showed that a RCD activity-defective
La mutant (La∆RCD, Figure 6A) cannot assist the restructuring of RNA stem-loops or
increase the expression of reporters regulated by highly structured 5′UTRs [16]. Hence,
to test whether the RNA chaperone activity of La is also required for the expression of
EMT and CSC markers, we overexpressed gfp-tagged La wildtype (LaWT) and the RCD
activity-defective La mutant (La∆RCD) in La-depleted cells. Strikingly, the TGFβ-induced
expression of mesenchymal marker N-cadherin, EMT marker vimentin, and cancer stem
cell marker Bmi1 was rescued by transient expression of La wildtype (LaWT) but not by
the RCD activity-defective La mutant (La∆RCD) (Figure 6B). Taken together, these data
implicate that the RNA chaperone activity of La contributes to TGFβ-induced EMT and
increased expression of CSC markers.
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Figure 6. Mutation of the RNA chaperone domain (RCD) activity blocks the rescue of TGFβ-induced,
La-dependent EMT and cancer stem cell marker expression in La-depleted cells. (A) Scheme of La
wildtype (WT) and RNA chapero dom in activity-defective mutant (∆RCD). (B) Transient expres-
sion of green fluorescence (gfp)-tagged La∆RCD was reduced, but LaWT rescued the expression
of me enchy al marker N-cadh rin, EMT marker vimentin, and canc r s em cell marker Bmi1 in
TGFβ-treated SCC22A cells. IB: immunoblot. TGFβ (plus) [5 ng/mL] or vehicle (minus) [1 mg/mL
BSA in 4 mM HCl] treatment (n = 2). Numbers below the bands represent the protein expression
nor lized to GAPDH.
Next, we examined whether the La protein supports three-dimensional (3D) sphere
formation and growth. Control or La-depleted SCC22A cells were plated in ultra-low
attachment plates in the presence of TGFβ or a vehicle-supplemented serum-free medium.
The number and size of spheres was determined on day six of culture. Phase contrast
microscopic images demonstrated that the La protein is required for sphere formation and
growth (Figure 7A). Quantification revealed a significant decrease in the number of spheres
formed (sphere formation) by La-depleted SCC22A cells (Figure 7B). Furthermore, the
size of spheres (sphere growth) was significantly diminished (Figure 7C), suggesting that
the proliferation defect mediated by La depletion contributes to reduced sphere growth.
Taken together, the data indicate that the RBP La supports the formation and growth
of spheres, a well-known hallmark of a CSC phenotype. However, it remains an open
question whether La conveys the positive effect on sphere formation and growth in a direct
or indirect manner.
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2.4. TGFβ Treatment Induces AKT-Mediated Phosphorylation of La at Threonine 389
The RBP La is post-translationally modified by phosphorylation [7,25] and sumoyla-
tion [26,27]. Recently, we described a novel PTM and demonstrated phosphorylation of
recombinant La at threonine 389 (T389) by AKT in an in vitro phosphorylation assay [16].
Furthermore, La wildtype but not La harboring a mutation in the phosphorylation site
(LaT389A) enhances cyclin D1 internal ribosome entry site (IRES)-mediated reporter assay
translation in cells. To continue to study the role of T389 phosphorylation on endogenous
La (pLaT389), we applied a pLaT389-specific antibody. The specificity of the antibody detect-
ing LaT389 phosphorylation was validated in La-depleted cells and with recombinant La
protein by immunoblot analysis (not shown).
Above, we have shown that La promotes TGFβ-induced EMT. Several signaling
pathways respond to TGFβ, such as the canonical SMAD pathway, but also noncanonical
pathways including AKT, ERK, and MAPK [28]. Therefore, it is reasonable to speculate
that TGFβ triggers AKT phosphorylation of La during EMT. To test this assumption, we
treated SCC22A cells with TGFβ or vehicle and harvested cell lysates at different time
points. Our studies showed that TGFβ increases T389 phosphorylation over time, start-
ing with a slight pLa T389 signal at 0.5 h, which strongly increased over 12 h (Figure 8A
and Figure S5). To test whether AKT stimulation correlates with T389 phosphorylation,
we treated cells with insulin, a classical activator of AKT, in the presence of increasing
pan-AKT inhibitor MK2066 concentrations. As expected, insulin stimulation induced AKT
activation, as shown by AKT phosphorylation at serine 473 (pAKTS473), which was inhib-
ited by increasing MK2066 concentrations (Figure 8B). Interestingly, increasing MK2066
concentration concurrently reduced pLaT389 phosphorylation. Further analysis revealed
that TGFβ-induced phosphorylation of LaT389 correlates with phosphorylation of AKTS473
and that TGFβ-induced phosphorylation of both target proteins were inhibited by MK2066
(Figure 8C). Taken together, these data support the notion that TGFβ treatment triggers
AKT-mediated phosphorylation of La at T389.
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Figure 8. TGFβ treatment increases phosphorylation of La at T389. (A) SCC22A cells cultured in
serum-free medium were treated with TGFβ [5 ng/mL] or vehicle [1 mg/mL BSA in 4 mM HCl]
for increasing time intervals from 0.5 to 1 h. (B) SCC22A cells cultured in serum-free medium were
treated with increasing MK2066 concentrations [0–10 µM] for 3 h followed by insulin treatment
[1 µM] for 15 min. (C) SCC22A cells cultured in serum-free medium were treated with MK2066
[10 µM] r vehicle for 3 h followed by treatment with TGFβ [5 ng/mL] or vehicle [1 mg/mL BSA in
4 mM HCl] for 1 h. IB: immunoblot. Numbers below bands show the phosphorylation status of La or
AKT by calculation the ratio of pLaT389/La or pAKTS473/AKT. The untreated control was set to 1 in
relation to all other samples. GAPDH served as loading control.
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Knowing that TGFβ triggers La phosphorylation in 2D cultures, we were eager to
find out whether the growth transition from adherent to ultra-low attached sphere growth
changes the phosphorylation status of LaT389. Hence, we compared the phosphorylation
status of La in two-dimensional (2D) attachment cultures with 3D sphere cultures. Interest-
ingly, although TGFβ was present in both settings immunoblot analysis revealed that La
phosphorylation at T389 was significantly reduced in 3D sphere cultures compared to 2D at-
tachment cultures (Figure 9A,B and Figure S6). In summary, TGFβ triggers AKT-mediated
phosphorylation of LaT389 in 2D but not 3D cultures, suggesting a different functional state
of La in adherent cells and spheres.




Figure 9. More phosphorylation of La at T389 in 2D compared to 3D cultures. (A) Immunoblot (IB) 
of SCC22A cells 2D-cultured compared to SCC22A cells (3000 or 6000 cells plated) cultured on 
ultra-low attachment plates (3D sphere culture) in serum-free medium plus TGFβ [5 ng/mL]. (B) 
Quantitative analysis of the pLaT389/La protein ratio in 2D versus 3D cultures of SCC22A cells. The 
βTubulin served as loading control (p value < 0.001 (three asterisks), n = 3). 
3. Discussion 
Taken together, this study indicates that the RBP La is required for TGFβ-induced 
EMT and a cancer stem cell-like phenotype of cancer cells. The RNA chaperone domain 
of the La protein appears to have a pivotal function during this process as suggested by 
rescuing mesenchymal and CSC protein marker expression (N-cadherin, vimentin, Bmi1) 
with La wildtype but not RNA chaperone domain activity-defective La mutant protein. 
Furthermore, TGFβ treatment induces AKT-dependent phosphorylation of RBP La at 
T389—a novel posttranslational modification present in cancer cells growing in 2D attach-
ment, but not 3D sphere cultures. However, the underlying molecular mechanism re-
mains elusive and current work aims to clarify the role of the RNA chaperone La and its 
T389 phosphorylation status in cancer cell plasticity. 
Although EMT is primarily regulated at the transcriptional level, recent studies sug-
gest that RBP-regulated translation of selective target mRNAs is of importance as well 
[28–30]. For example, binding of RBP hnRNPE1 and translation elongation factor eEF1A1 
to the TGFβ-activated translational (BAT) RNA element blocks the translational elonga-
tion of target mRNAs and is released under TGFβ-induced EMT [31]. Furthermore, the 
overexpression of RBP YB1 in noninvasive breast cancer cells induces EMT and activates 
IRES-dependent translation of SNAIL1, a transcriptional master regulator of EMT [32,33]. 
Moreover, during EMT of murine hepatocellular carcinoma cells, the RBP La stimulates 
IRES-dependent translation of laminin B1, a critical extracellular matrix protein [13]. 
Those studies suggest that during EMT certain RNA-binding proteins can activate the 
translation of selective target mRNAs and thereby stimulate cancer progression. Along 
those lines, our study supports the hypothesis that RBP La stimulates the expression of 
transcriptional master regulator ZEB1 during EMT. La depletion reduced TGFβ-induced 
EMT and the expression of ZEB1 protein, but ZEB1 mRNA level were unchanged (data 
not shown), suggesting that the RNA chaperone La controls ZEB1 expression post-tran-
scriptionally. Interestingly, a predicted RNA folding of the ZEB1 5′UTR revealed a stem-
loop structure enclosing the authentic translation start site. Similar to studies on La in 
cyclin D1 and Bcl2 mRNA translation [9,14], we envision that the RNA chaperone activity 
of La is critical for efficient ZEB1 mRNA translation by unwinding impeding secondary 
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f the La protein a pears to have a pivotal function during this proces as suggested
by rescuing mesenchymal and CSC protein marker expression (N-cadherin, vimentin,
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protein. Furthermore, TGFβ treatment induces AKT-dependent phosphorylation of RBP
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attachment, but not 3D sphere cultures. However, the underlying molecular mechanism
remains elusive and current work aims to clarify the role of the RNA chaperone La and its
T389 phosphorylation status in cancer cell plasticity.
Although EMT is primarily regulated at the transcriptional level, recent studies
suggest that RBP-regulated translation of selective target mRNAs is of importance as
well [28–30]. For example, binding of RBP hnRNPE1 and translation elongation factor
eEF1A1 to the TGFβ-activated translational (BAT) RNA element blocks the translational
elongation of target mRNAs and is released under TGFβ-induced EMT [31]. Furthermore,
the overexpression of RBP YB1 in noninvasive breast cancer cells induces EMT and activates
IRES-dependent translation of SNAIL1, a transcriptional master regulator of EMT [32,33].
Moreover, during EMT of murine hepatocellular carcinoma cells, the RBP La stimulates
IRES-dependent translation of laminin B1, a critical extracellular matrix protein [13]. Those
studies suggest that during EMT certain RNA-binding proteins can activate the translation
of selective target mRNAs and thereby stimulate cancer progression. Along those lines,
our study supports the hypothesis that RBP La stimulates the expression of transcriptional
master regulator ZEB1 during EMT. La depletion reduced TGFβ-induced EMT and the
expression of ZEB1 protein, but ZEB1 mRNA level were unchanged (data not shown),
suggesting that the RNA chaperone La controls ZEB1 expression post-transcriptionally.
Interestingly, a predicted RNA folding of the ZEB1 5′UTR revealed a stem-loop structure
enclosing the authentic translation start site. Similar to studies on La in cyclin D1 and Bcl2
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mRNA translation [9,14], we envision that the RNA chaperone activity of La is critical
for efficient ZEB1 mRNA translation by unwinding impeding secondary structures and
thereby supporting effective translational initiation.
Recent work suggests that cellular functions of La are regulated by post-translational
modifications. For example, we have shown that a small ubiquitin-like modifier (SUMO)
of rat La regulates the retrograde transport in axons [34] and facilitates the RNA-binding
activity of human La in in vitro and cell-based assays [26,27]. Moreover, phosphorylation
of human La at serine 366 (pLaS366) by CK2 is the best-studied modification of the hu-
man La protein so far. It has been shown that pLaS366 localizes within the nucleoplasm,
whereas nonphosphorylated La resides in the cytoplasm and nucleolus [7,25]. Studies
suggest that phosphorylation of La at serine 366 regulates the binding and translation of
5′-terminal oligopyrimidine (TOP) mRNAs encoding ribosomal proteins and translation
elongation factors [35]. In case of murine La, it has been demonstrated that AKT-mediated
phosphorylation at threonine 301 induces the shuttling of RBP La from the nucleus to the
cytoplasm allowing the protein synthesis of oncogenic target mRNAs, contributing to an
oncoproteom in glioblastoma cells [36]. In TGFβ-treated mesenchymal hepatocytes, PDGF
and downstream MAPK/ERK-signaling regulates the cytoplasmic accumulation of murine
La [10]. More recently, we found that human La is phosphorylated at threonine 389 (T389)
by AKT in vitro and stimulates cyclin D1 IRES-mediated reporter expression in cell-based
assays [16]. The collective finding that AKT-mediated phosphorylation of mouse [36]
and human La [16], although at different threonine residues, modulates the translation of
target mRNAs is very interesting. The strong increase in pLaT389 after TGFβ treatment
suggests that the RNA chaperone La fosters TGFβ–induced EMT by facilitating translation
of a specific set of oncogenic target mRNAs, which are characterized by RNA structural
elements located close to the translational start codon in the 5′UTRs. Since our data show
that phosphorylation of LaT389 is significantly reduced in cancer cells growing as spheres
compared to 2D attachment cultures, the RNA chaperone activity might be reduced in
cancer cells expressing cancer stem cell properties necessary for metastatic spread. In future
studies we will focus on the interplay between post-translational modifications regulating
the RNA chaperone activity of La during translation of mRNAs encoding factors regulating
cancer cell plasticity and metastasis.
4. Materials and Methods
4.1. Cell Culture and ShRNA Transduction
Both the lung cancer cell line A549, purchased from ATCC, and head and neck cancer
cell line UM-SCC 22A (SCC22A) [8,37] were expanded and stored in liquid nitrogen. Cell
lines were cultured in advanced DMEM (Gibco/Thermo Fisher Scientific, Inc., Waltham,
MA, USA) containing 2 mM L-glutamine (Life Technology/Thermo Fisher Scientific, Inc.,
Waltham, MA, USA), Penicillin-Streptomycin (Gibco), plus 10% FBS. For three-dimensional
(3D) sphere cultures, cells were plated in ultra-low attachment 24-well plates (Corning
Costar, Corning, NY, USA) in serum-free medium containing TGFβ [5 ng/mL] or vehicle
(1 mg/mL BSA in 4 mM HCl) and cultured for 6 days before analysis. All cell lines were
tested for mycoplasma contamination by applying MycoSensor PCR Assay kit according
to manufacturer’s instructions (Agilent Technologies, Inc., Santa Clara, CA, USA). For La-
specific shRNA-mediated depletion lentiviral transduction of MISSION shRNA constructs
(TRCN0000062193 and TRCN0000062195) were performed according to the manufacture’s
instruction (Sigma-Aldrich, St. Louis, MO, USA). All lentiviral experiments were performed
under biosafety level S2 at our laboratory at the Medical University of South Carolina
(Charleston, SC, USA).
4.2. Transfection of Gfp-Tagged La Plasmids
Green fluorescence protein (gfp)-tagged wildtype La (WT) and RNA chaperone do-
main activity-defective mutant La (∆RCD) has been described recently [16]. For transfection
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a nucleofector was applied according to the manufacturer’s instructions (Nucleofector
Kit V, program U-029, AMAXA, Inc., Seattle, WA, USA).
4.3. Immunohistochemistry
The immunohistochemical staining was performed as described recently by applying
the monoclonal human La-specific 3B9 antibody as detailed described in [8,9] on two
distinct lung cancer tissue microarrays (TMA: BC04118 and LC1002, US Biomax, Inc.,
Derwood, MD, USA). The predominantly nuclear staining of the RBP La is depicted
as percentages based on the largest population of benign cells present in normal tissue,
respectively, tumor cells present in cancer tissue.
4.4. Proliferation and Wound healing Assay
Proliferation rates were determined as described recently by applying the CyQuant
Cell Proliferation Assay Kit (Invitrogen/Thermo Fisher Scientific, Inc., Waltham, MA,
USA) [9]. The numbers of reattached cells was determined 5 h after seeding (FU = fluores-
cence units). Wound healing assay was performed as described previously [8].
4.5. Immunoblot Analysis
Cells were lysed and protein was analyzed by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). The following antibodies were applied: monoclonal human La-specific 3B9
antibody [38], anti-N-cadherin (#14215, Cell Signaling Technology, Inc., Danvers, MA,
USA), anti-ZO-1 (#8193, Cell Signaling), anti-Vimentin (#5741, Cell Signaling), anti-CD44
(#3570, Cell Signaling), anti-Bmi1 (#5856, Cell Signaling), anti-ZEB1 (#3398, Cell Signaling),
anti-AKT (#4591, Cell Signaling), anti-pAKT (#4060, Cell Signaling), anti-GAPDH (#25778,
Santa Cruz Biotechnology, Inc., Dallas, TX, USA), and anti-tubulin (#5568, Cell Signaling).
The affinity-purified polyclonal rabbit anti-pLaT389 against threonine 389 phosphorylated
human La peptide (amino acids 381–393) was generated by YenZym antibodies, LCC, Bris-
bane, CA, USA. Secondary antibodies were horseradish peroxidase-conjugated (Dianova,
Inc., Pine Bush, NY, USA).
4.6. Statistical Considerations
Two-tailed p-value was determined by t-test, applying Prism (Version 5, GraphPad
Software, San Diego, CA, USA). p-value < 0.05 (one asterisks), <0.005 (two asterisks),
and <0.001 (three asterisks). Error bars represent the mean +/− SD of triplicates in n-
independent experiments.
5. Conclusions
This study indicates that cancer-associated elevated expression of RBP La is critical
for TGFβ-induced EMT and the acquisition of cancer stem cell properties. The RNA
chaperone domain of La appears to own a pivotal function during this process as suggested
by rescuing vimentin and Bmi1 expression with La wildtype, but not RNA chaperone
domain activity-defective La mutant protein. Furthermore, TGFβ treatment induces AKT-
dependent phosphorylation of La at T389—a novel posttranslational modification—present
in cancer cells growing in 2D adherent but not 3D sphere cultures. Our study suggests
that the TGFβ/AKT/pLaT389 signaling pathway regulates cancer cell plasticity. Since
the underlying molecular mechanism and its implication for the cancer cell plasticity
remains elusive, current work aims to clarify the role of the RNA chaperone La and its
T389 phosphorylation status during cancer progression and metastasis.
During cancer progression and metastatic colonization the tumor microenvironment is
of key importance. Within the tumor microenvironment secreted cytokines and chemokines
act as autocrine and paracrine signals and mediate cross-talk between cancer cells, cancer-
associated fibroblasts, immune cells, smooth muscle cells, and endothelial cells. In particu-
lar, TGFβ signaling has emerged as key player in the tumor microenvironment triggering
tumor growth, metastasis and therapy resistance [39,40]. It will be interesting to address
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in future studies the open question to which extent the TGFβ/AKT/pLaT389 signaling
pathway is involved in shaping the tumor microenvironment to drive cancer progression.
Our data emphasize a functional role of the RBP La during cancer progression. Aiming
to identify an interventional La inhibitor for anticancer therapy, we received first promising
data applying a La-based fluorescence polarization high throughput screening assay to
screen a library of small molecular compounds for molecules able to block La:mRNA
interactions [41]. As a first hit, we identified a small compound able to selectively block the
binding of La to target mRNA containing a stem-loop structure in the 5′UTR (antiapoptotic
factor Bcl2) and did not affect binding of La to mRNAs containing 5′UTRs with terminal
oligopyrimidine tracts (TOP mRNAs), which have been shown to interact with the RNA-
binding protein La such as ribosomal proteins rpL37 and rpL5. Our future studies are
warranted to further investigate if the RBP La is a valid target for therapeutic intervention.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-669
4/13/2/343/s1, Figure S1: Overexpression of RBP La in lung cancer tissue analyzed by cancer stage,
Figure S2: Overexpression of RBP La in lung cancer tissue analyzed by sex, Figure S3: Supplemental
Figures 4 and 5, Figure S4: Supplemental Figure 6, Figure S5: Supplemental Figure 8, Figure S6:
Supplemental Figure 9.
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